• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    Pfizer, BioNTech Adapt COVID Vax Against Omicron

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Biosynth Carbosynth

    Kyongbo Pharmaceutical

    Vector Partners Limited

    Qosina
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Biosynth Carbosynth

    Kyongbo Pharmaceutical

    Vector Partners Limited

    Qosina
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    The ADC Market is Fast Evolving

    Applications of ADCs are widening and improvements in the manufacturing process meet industry requirements.

    The ADC Market is Fast Evolving
    Related CONTENT
    • Vetio Animal Health
    • 5 ADC Manufacturing Challenges You Need To Know
    • The 20th Annual Salary Survey
    • Budgeting, Resource Management, and Outsourcing for Clinical Trials
    • Sanofi Names New CEO
    Charlie Johnson, CEO, ADC Bio06.13.19
    The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat multiple diseases and innovative new biopharmaceuticals to further enhance the treatment of cancer. The effectiveness of antibody drug conjugates (ADCs) and checkpoint inhibitors in combating cancer is having a massive impact on the ADC R&D market; additionally, new and exciting uses of antibody drug conjugates are also being actively researched. Data analysis by Beacon Targeted Therapies highlights this significant ADC market trend.

    As the number of ADCs used in drug development and actual healthcare treatment expands, so does pressure to intensify their development, driving advanced manufacturing techniques and supply chain innovation.

    Growth in new ADC uses
    The ADC biopharmaceuticals sector has seen a big trend towards R&D into new uses of ADCs—both in terms of combination drugs for treating cancer and the application of the drug class for the treatment of other diseases beyond the realm of cancer indications.

    Research has shown that antibody drug conjugates have application as anti-inflammatory agents, anti-microbials and anti virals. Analysis by Beacon Targeted Therapies shows that clinical trials for ADCs are already underway to test their effectiveness in treating a number of non-cancer indications. There are currently nine trials that are focused on diffuse cutaneous systemic sclerosis, systemic sclerosis, Graft vs. Host Disease (GVHD), myeloproliferative neoplasm and myelodysplastic syndrome, HIV-1-infection, systemic lupus erythematosus, methicillin-sensitive staphylococcus aureus (MSSA), methicillin-resistant staphylococcus aureus (MRSA) and bacteraemia. The ADCs that are being used in this research include Brentuximab Vedotin and RG7861. The RG7861 antibody drug conjugate is an anti-Staphylococcus aureus ADC conjugated to dmDNA3.1 payload. The ADC is being studied in two phase I trials for S. aureus bacteraemia. 

    Furthermore, phase I studies are also underway into rheumatoid arthritis treatment using ABBV-337 which is based on Adalimumab (anti-TNFalpha) conjugated with a glucocorticoid receptor. This treatment has a different mode of action to that of brentuximab-based depletion of T-Cells.

    In oncology, Beacon Targeted Therapies analysis shows that the total number of active clinical trials of ADC/Checkpoint Modulator combination drugs is 40. Checkpoint inhibitors most frequently used in combination with ADCs include  Nivolumab, Pembrolizumab and Atezolizumab (see Table 1).


    Table 1. ADC & Checkpoint Combination Trials

    Of the 14 trials studying pembrolizumab in combination with different ADCs, four trials are in phase II. The disease indications include myeloma, endometrial cancer, breast cancer and melanoma. Six trials are in phase I/II and the disease indications studied include cervical cancer, ovarian cancer, breast cancer, DLBCL, Hodgkin lymphoma, melanoma and other solid tumors. 

    A total of 20 trials are studying combination of nivolumab and ADCs. Nivolumab in combination with BV is in phase III studies for Hodgkin lymphoma. Eight trials are studying ADCs in combination with nivolumab in phase 2 trials, mostly for Hodgkin lymphoma (only one trial is studying the combination for melanoma). Various studies for other solid tumors are mostly in phase I or phase I/II.  

    A total of six trials are evaluating atezolizumab in combinations with ADCs. One phase II trial is evaluating the combination in breast cancer. All other trials are still in phase I or phase I/II and evaluating the combinations in indications including breast cancer, DLBCL, follicular lymphoma, non-small cell lung cancer, urothelial and bladder cancer. 

    Pre-clinical studies using monoclonal antibodies to target non-cytotoxic drugs are growing. In the immune-oncology space, for example, the use of the antiCD11a mAb is being utilized to target a phosphodiesterase 4 inhibitor to improve the therapeutic index of the highly potent anti-inflammatory drug1 or liver X receptor agonists for an atherosclerosis indication.2

    Chemical conjugation can be used instead of the fusion protein route to target a protein toxin or function protein. Examples of this include urease delivery, lintuzumab gelonin (L-DOS47),3 ricin toxin A;  targeted delivery of siRNA4 and the formation of chemical conjugated Fab fragment based bispecifics.5

    The ever increasing diversity of ADCs is reflecting a move to the targeted approach for a wider range of bioactives is important and must not be inhibited by the well-known supply chain complexity and cost of manufacturing.

    The impact of ADC manufacturing innovation
    Innovation is needed to shorten the development time of ADCs and to achieve cost savings in the ADC production. There is at present too complex a set of manufacturing processes carried out across multiple vendors in different geographic locations.

    Advanced manufacturing process innovation
    There is great potential for further development and greater application of optimized process solutions by the CDMO industry to significantly enhance efficiency. A cutting edge  example is the opportunity to utilize tools developed specifically for ADC development and manufacturing such as Lock-Release. This technique streamlines bioconjugation into four simple steps. The technology locks the antibody (mAb) to a resin, performs the conjugation, washes the locked ADC free of residuals and then releases the purified ADC.

    The technology is central to a new integrated bioconjugation concept that is being verified—a technique in which one combined process achieves both mAb purification and conjugation. This integration of the Lock-Release-mediated ADC process into the platform mAb process is transformational. Lock-Release starts with antibody supernatants and facilitates both the antibody capture step and subsequent conjugation of the toxin-linker to generate the ADC.

    Consequently, the starting point for conjugation will no longer be constrained to the use of purified antibodies as with this new process, it can instead begin anywhere between first capture of the mAb from the cell culture supernatant onto an affinity Lock-Release resin and the final stage mAb process operations typically employed. Due to the fact that this involves the handling of highly potent cytotoxins, it will require the conjugation and purification processes to be carried out by integrated bioconjugation CDMOs with the necessary high containment infrastructure. The regulatory requirements for viral inactivation, viral clearance and final polishing steps can then be met post-conjugation.

    An integrated process saves an estimated 8 months in preparing Phase I material from a defined ADC candidate—24 months instead of 32.  This approach treats the antibody as a process intermediate rather than qualified drug substance. The technique eliminates repeated incoming QC analytics, mAb formulation and stability, shipping delays/risks and separate scale-up studies, reduces material wastage and involves less contingency planning. Compression of timelines by 8 months is critical in an oncology setting, and can be the difference between a life-saving or life extending option for patients.

    Lock-Release affinity resins enhance the integration of the conjugation step into the mAb platform process, by providing both purification capability and compatibility with conjugation conditions.

    This innovative, advanced manufacturing technique would revolutionize the ADC production industry—seeing the industry shift from the current separated process approach to one in which the entire supply chain is considered as a continuum with only the final ADC considered as a product.

    The integrated process enables supply chain optimization; one CDMO facility can perform operations typically provided by 2 or 3 service providers (or separate facilities of one provider). The advantages of such an integrated process platform outweigh the effort involved in its development, validation, operational risk assessment and implementation of facility segregation.

    Conclusion
    The market is seeing significant growth in studies focused on the use of ADCs to treat other diseases and conditions beyond the realm of cancer with the numbers of such drugs in active clinical trials growing monthly. Furthermore, the use of ADCs in combination with checkpoint inhibitors is a further growth area in anti-cancer treatment with a large number of such biopharmaceuticals now in clinical trials.

    The ADC drug market is set to see significant advances in manufacturing efficiency with the improvements achieved through process innovation. This will include the integration of bioconjugation with mAB purification through a highly novel downstream development process which provides the benefit of just one set of manufacturing, analytical development and release processes, reduces costs and speeds up manufacturing and development time by as much as 8 months. For drug developers who historically have been ultra-conservative in adopting changes to tried and tested manufacturing methods, the allure of significant extension of patent protection is a compelling reason to seriously consider early implementation of integrated processes. 

    References
    1. Yu, Shan, Aaron D Pearson, Reyna KV Lim, David T Rodgers, Sijia Li, Holly B Parker, Meredith Weglarz, et al. “Targeted Delivery of an Anti-Inflammatory PDE4 Inhibitor to Immune Cells via an Antibody–Drug Conjugate.” Molecular Therapy 24, no. 12 (December 1, 2016): 2078–89. https://doi.org/10.1038/mt.2016.175.
    2. Lim, Reyna K. V., Shan Yu, Bo Cheng, Sijia Li, Nam-Jung Kim, Yu Cao, Victor Chi, et al. “Targeted Delivery of LXR Agonist Using a Site-Specific Antibody–Drug Conjugate.” Bioconjugate Chemistry 26, no. 11 (November 18, 2015): 2216–22. https://doi.org/10.1021/acs.bioconjchem.5b00203
    3. Duzkale, Hatice, Lance C. Pagliaro, Michael G. Rosenblum, Ali Varan, Baoshun Liu, James Reuben, William G. Wierda, et al. “Bone Marrow Purging Studies in Acute Myelogenous Leukemia Using the Recombinant Anti-CD33 Immunotoxin HuM195/RGel.” Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 9, no. 6 (June 2003): 364–72.
    4. Duzkale, Hatice, Lance C. Pagliaro, Michael G. Rosenblum, Ali Varan, Baoshun Liu, James Reuben, William G. Wierda, et al. “Bone Marrow Purging Studies in Acute Myelogenous Leukemia Using the Recombinant Anti-CD33 Immunotoxin HuM195/RGel.” Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 9, no. 6 (June 2003): 364–72.
    5. Kim, Chan Hyuk, Jun Y. Axup, Anna Dubrovska, Stephanie A. Kazane, Benjamin A. Hutchins, Erik D. Wold, Vaughn V. Smider, and Peter G. Schultz. “Synthesis of Bispecific Antibodies Using Genetically Encoded Unnatural Amino Acids.” Journal of the American Chemical Society 134, no. 24 (June 20, 2012): 9918–21. https://doi.org/10.1021/ja303904e.


    Charlie Johnson is chief executive officer of ADC Bio (www.adcbio.com). He brings over 20 years of experience in strategic development, commercialization and management of service businesses within the oncology sector. His track record in the ADC segment goes back to 2004 when he established Avecia’s ADC manufacturing operations when the segment was in its infancy. Prior to joining ADC Biotechnology as chief executive in early 2012, Mr. Johnson held positions as director for the high potency division of Dishman Group’s Carbogen Amcis operation, headquartered in Basel and as business manager for the strategic marketing of the oncology portfolio of Italy’s UQUIFA. He previously held a series of pharma-related roles with ICI and Astra Zeneca.      
    Related Searches
    • chief executive officer
    • cancer
    • manufacturing operations
    • Analytical Development
    Suggested For You
    Vetio Animal Health Vetio Animal Health
    5 ADC Manufacturing Challenges You Need To Know 5 ADC Manufacturing Challenges You Need To Know
    The 20th Annual Salary Survey The 20th Annual Salary Survey
     Budgeting, Resource Management, and Outsourcing for Clinical Trials Budgeting, Resource Management, and Outsourcing for Clinical Trials
    Sanofi Names New CEO Sanofi Names New CEO
    Nitrosamines Nitrosamines
    PCI Clinical Services to Host Seminars PCI Clinical Services to Host Seminars
    Vertex Takes a Risk-based Approach to UAT Vertex Takes a Risk-based Approach to UAT
    The New Horizon: Metaprise Analytics in Life Sciences The New Horizon: Metaprise Analytics in Life Sciences
    Boehringer, IBM Explore Blockchain Technology in Clinical Trials Boehringer, IBM Explore Blockchain Technology in Clinical Trials
    IQVIA Launches IQVIA Biotech IQVIA Launches IQVIA Biotech
    CDMOs On The Rise CDMOs On The Rise
    Quanticate Launches QVigilance Quanticate Launches QVigilance
    Managing Outsourced Clinical Trials Managing Outsourced Clinical Trials

    Related Content

    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19

    • 5 ADC Manufacturing Challenges You Need To Know

      5 ADC Manufacturing Challenges You Need To Know

      Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.

    • The 20th Annual Salary Survey

      Plus: packaging trends, data integrity, serialization, ADCs and expediting clinical development
      Tim Wright, Editor 06.13.19


    • Budgeting, Resource Management, and Outsourcing for Clinical Trials

      ...
      06.12.19

    • Industry News
      Sanofi Names New CEO

      Sanofi Names New CEO

      Paul Hudson to succeed Olivier Brandicourt as of September 1st
      06.07.19

      Loading, Please Wait..
      Trending
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • 17th Annual Contracting & Outsourcing Conference Photos
      • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
      • LabVantage Solutions Adds Mixed Reality Technology to Its Advanced LIMS Platform
      • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
      Breaking News
      • Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • CoreRx Expands Capabilities
      • Qosina Strengthens Aseptic Capabilities
      • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Japanese Mushroom Extract Appears Helpful in HPV Infections
      Fi & Hi Europe Returns with Over 20,000 Global Attendees Expected
      United Plant Savers Launches First Film Festival
      Coatings World

      Latest Breaking News From Coatings World

      Vaughn O’Dea Named Director of Epoxytec
      Dr. Tammo Boinowitz to Join ALTANA's Management Board
      Hempel Launches New Fast-drying CUI Coating
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Accelmed Partners II, Lauxera Capital Partners Invest in Veranex
      Agnes Lee Named SVP of Investor Relations, Strategic Planning at Inogen
      Dr. Brandee Pappalardo Joins Fresenius Kabi as Chief Medical Officer
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      Pfizer, BioNTech Adapt COVID Vax Against Omicron
      CoreRx Expands Capabilities
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Top 5 Beauty Tech Trends at Perfect Corp.'s Global Forum
      John Frieda Supports the LGBTQIA+ Community
      Athena Club Launches in Canada
      Happi

      Latest Breaking News From Happi

      Color Street Celebrates Foster, Adoption Awareness with Limited-Edition Print
      CIR Panel Conducts 161st Meeting Regarding Safety Assessments for Cosmetic Ingredients
      DIY Nail Care Is Outperforming the Professional Segment: Kline
      Ink World

      Latest Breaking News From Ink World

      Dr. Tammo Boinowitz to Join Management Board of ALTANA AG
      Flint Offset Packaging Solutions Announces Price Increases for Sheetfed Inks
      Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Harveer Sahni recognized with Global Achievement Award
      Color-Logic partners with Taktiful 
      ALTANA announces Management Board change
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Fibertex Personal Care Awarded EcoVadis Awards for Sustainability
      Yanpai Orders Batt Forming Equipment for Needlepunch Line
      Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Researchers Discover Novel Patching Material for Bone Defects
      Boston Centerless Opens Second Manufacturing Plant in Indiana
      Researchers Develop Patient-Specific 3D-Printed Smart Metamaterial Implants
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Identiv-Powered CVS Spoken Rx Wins NFC Forum 2022 Innovation Award
      LG Display Announces Winners of This Year’s OLEDs GO! Competition
      Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login